Switch theme
Sign up to access all valuation multiples
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
2010
233
LTM Revenue $4.2M
LTM EBITDA -$109M
$176M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Seres Therapeutics has a last 12-month revenue of $4.2M and a last 12-month EBITDA of -$109M.
In the most recent fiscal year, Seres Therapeutics achieved revenue of n/a and an EBITDA of -$120M.
Seres Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Seres Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $126M | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$94.3M | -$120M | XXX | XXX | XXX |
| EBITDA Margin | -75% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$250M | -$114M | XXX | XXX | XXX |
| Net Margin | -198% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Seres Therapeutics's stock price is $1.
Seres Therapeutics has current market cap of $116M, and EV of $176M.
See Seres Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $176M | $116M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Seres Therapeutics has market cap of $116M and EV of $176M.
Seres Therapeutics's trades at 41.7x LTM EV/Revenue multiple, and -1.6x LTM EBITDA.
Analysts estimate Seres Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Seres Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $176M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -1.5x | XXX | XXX | XXX |
| P/E | 850.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSeres Therapeutics's NTM/LTM revenue growth is 148%
Seres Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Seres Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Seres Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Seres Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 28% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Seres Therapeutics acquired XXX companies to date.
Last acquisition by Seres Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Seres Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Seres Therapeutics founded? | Seres Therapeutics was founded in 2010. |
| Where is Seres Therapeutics headquartered? | Seres Therapeutics is headquartered in United States of America. |
| How many employees does Seres Therapeutics have? | As of today, Seres Therapeutics has 233 employees. |
| Who is the CEO of Seres Therapeutics? | Seres Therapeutics's CEO is Mr. Eric D. Shaff. |
| Is Seres Therapeutics publicy listed? | Yes, Seres Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Seres Therapeutics? | Seres Therapeutics trades under MCRB ticker. |
| When did Seres Therapeutics go public? | Seres Therapeutics went public in 2015. |
| Who are competitors of Seres Therapeutics? | Similar companies to Seres Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Seres Therapeutics? | Seres Therapeutics's current market cap is $116M |
| What is the current revenue of Seres Therapeutics? | Seres Therapeutics's last 12-month revenue is $4.2M. |
| What is the current EBITDA of Seres Therapeutics? | Seres Therapeutics's last 12-month EBITDA is -$109M. |
| What is the current EV/Revenue multiple of Seres Therapeutics? | Current revenue multiple of Seres Therapeutics is 41.7x. |
| What is the current EV/EBITDA multiple of Seres Therapeutics? | Current EBITDA multiple of Seres Therapeutics is -1.6x. |
| Is Seres Therapeutics profitable? | Yes, Seres Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
